Business Wire

Uptime’s 13th Annual Global Data Center Survey Shows Widening Range of Challenges

18.7.2023 13:03:00 EEST | Business Wire | Press release

Share

Uptime Institute today announced the release of its 13th Annual Global Data Center survey. The findings show data center operators facing stricter regulations and more pressure to reduce energy, along with persistent staffing and supply chain issues. The Report shows new technologies potentially presenting a promising way forward, but these often are found lacking in standardization and scalability. While for many organizations, investments in efficiency and resiliency are beginning to pay off, progress has been gradual.

“Our data shows operators grappling with several issues,” said Andy Lawrence, executive director, Uptime Intelligence. “In 2023, the lingering effects of the COVID-19 pandemic have receded, but other challenges have emerged. Digital infrastructure managers are now most concerned with improving energy performance and dealing with staffing shortfalls, while Government regulations aimed at improving data center sustainability and visibility are beginning to require attention, investment, and action.”

Uptime’s Annual Global Data Center survey is the largest, most comprehensive, and longest-running study in the digital infrastructure sector. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2023 report include:

  • Average global power usage effectiveness (PUE) levels have remained flat for four years. Additional improvements in PUE levels will require significant investment.
  • As more organizations opt for a hybrid approach to IT, the share of enterprise workloads that are run in corporate, on-premises facilities has fallen to below half for the first time and is expected to shrink further.
  • Enterprise operators say data security is the biggest impediment to moving mission-critical workloads to the public cloud. Resiliency and transparency are lesser concerns.
  • Server rack densities are climbing steadily, but slowly. Average rack densities are below 6 kilowatt (kW) per rack; most operators do not have any racks beyond 20 kW. This suggests the widespread use of direct liquid cooling is not imminent.
  • Many operators only collect a limited amount of sustainability related data and will struggle to meet emerging sustainability reporting requirements, or in turn, the requirements of some customers and the public.
  • Most operators believe acceptance of the use of artificial intelligence will grow in data centers, but operators are distrustful of its ability to make reliable operational decisions.

Outages:

  • More than half (55%) of operators reported they have had an outage at their site in the past three years, the lowest number yet recorded. This continues a trend of steady improvement.
  • Power outages continue to be cited as the single biggest cause of outages.

Staffing:

  • Uptime Intelligence data shows that approximately 8% of the data center workforce are women. In the US (if not all countries), this rate is below that of other male-dominated industries, such as mining and construction.
  • Nearly two-thirds of operators have problems recruiting or retaining staff – however, this figure is not currently growing. The largest skill gaps are in operations, mechanical and electrical roles.

About the Survey:

Uptime conducted this year’s annual Global Data Center Survey online from February – April 2023 and collected responses from more than 850 data center owners and operators and nearly 700 vendors and consultants.

Learn More:

Uptime’s 2023 Global Data Center Survey also includes findings on regulatory support, sustainability, and metrics, staffing shortfalls, skills gaps, diversity, innovation and impact, and more. Download the executive summary report here and register for the webinar covering its key trends and takeaways on July 18th at 12:00 PM EDT, 5:00 PM BST.

About Uptime:

Uptime Institute is the Global Digital Infrastructure Authority. For over 25 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. With its Tier Standard and Certifications, Management & Operations reviews, SCIRA-FSI financial sector risk assessment, broad range of additional risk and performance assessments, intelligence research service, and training courses completed by over 10,000 data center professionals, Uptime has helped thousands of companies in over 114 countries to optimize critical IT assets while managing costs, resources, and efficiency.

Uptime Institute is headquartered in New York, NY, with offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei. For more information, please visit www.uptimeinstitute.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brenda South
206/706-4647
bsouth@uptimeinstitute.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye